Claus Jørgensen

University of Manchester — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

35h-index9.1kcitations132works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(24), Cancer Immunotherapy and Biomarkers(19), Cancer Cells and Metastasis(15), Pancreatic and Hepatic Oncology Research(14), Advanced Proteomics Techniques and Applications(14)

Publications132 total

Abstract C045: Targeting metabolic heterogeneity in pancreatic ductal adenocarcinoma
Cancer Research·2024Open Access
Abstract 2494: RAS-Bio a unique pan-cancer biobank for RAS-driven tumors
Cancer Research·2024
Abstract B020: Charting the cellular heterogeneity of primary and metastatic PDAC microenvironment
Cancer Research·2024
Abstract A099: Utilising interactomics to uncover oncogenic KRAS signalling networks in the context of the tumor microenvironment
Cancer Research·2024
Factors influencing functioning after volar locking plate fixation of distal radius fractures: a scoping review of 148 studies
Acta Orthopaedica·2023· 4 citedOpen Access
FAK scaffolds immune escape in pancreatic cancer
Gut·2023· 3 cited
Supplementary Table S2 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Supplementary Material from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Supplementary Table S3 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Table S1 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Table S3 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Table S2 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Supplementary Table S3 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Data from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Supplementary Figure S2 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Data from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
Table S6 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Table S3 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Table S7 from Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
2023Open Access
Supplementary Table S6 from Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Karsten Kristiansen(10), Tony Pawson(9), Rune Linding(8), John Sinclair(7), Jonathan D. Worboys(7), Adrian Pasculescu(5), Christopher J. Tape(5), Rasmus K. Petersen(5), Philip Hallenborg(5), Kelly McMahon(4), Douglas A. Lauffenburger(4), Colin Hutton(4), Jonathan D. Humphries(4), Martin J. Humphries(4), Anne Krogsdam(4), Irina Kratchmarova(4), Susanne Mandrup(4), Ida C. Norrie(3), George Poulogiannis(3), Adrián Blanco‐Gómez(3)